

Additional File 1. 361 Breast Cancer Gene Sets that were Utilized in GSEA

NAME	ORIGINAL SIZE	AFTER RESTRICTING TO DATASET	STATUS
AIGNER_ZEB1_TARGETS	35		28
AIYAR_COBRA1_TARGETS_DN	29		22
AIYAR_COBRA1_TARGETS_UP	39		31
BAE_BRCA1_TARGETS_DN	32		29
BAE_BRCA1_TARGETS_UP	75		64
BCAT_BILD_ET_AL_DN	46		33
BCAT_BILD_ET_AL_UP	49		32
BECKER_TAMOXIFEN_RESISTANCE_DN	52		39
BECKER_TAMOXIFEN_RESISTANCE_UP	50		44
BENPORATH_CYCLING_GENES	648		457
BENPORATH_EED_TARGETS	1062		712
BENPORATH_ES_1	379		281
BENPORATH_ES_2	40		25
BENPORATH_ES_CORE_NINE	9		8
BENPORATH_ES_CORE_NINE_CORRELATED	100		84
BENPORATH_ES_WITH_H3K27ME3	1118		776
BENPORATH_MYC_MAX_TARGETS	775		599
BENPORATH_MYC_TARGETS_WITH_EBOX	230		197
BENPORATH_NANOG_TARGETS	988		694
BENPORATH_NOS_TARGETS	179		132
BENPORATH_OCT4_TARGETS	290		214
BENPORATH_PRC2_TARGETS	652		449
BENPORATH_PROLIFERATION	147		118
BENPORATH_SOX2_TARGETS	734		522
BENPORATH_SUZ12_TARGETS	1038		698
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_DN	169		119
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP	206		142
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN	88		69
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP	211		147
BHAT_ESR1_TARGETS_VIA_AKT1_DN	82		61
BHAT_ESR1_TARGETS_VIA_AKT1_UP	281		187
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_DN	127		88
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP	125		86
BIOCARTA_ATRBRCA_PATHWAY	21		18
BIOCARTA_HER2_PATHWAY	22		20
BIOCARTA_STATHMIN_PATHWAY	19		16
CAFFAREL_RESPONSE_TO_THC_24HR_3_DN	13		10
CAFFAREL_RESPONSE_TO_THC_24HR_3_UP	8		6
CAFFAREL_RESPONSE_TO_THC_24HR_5_DN	59		45
CAFFAREL_RESPONSE_TO_THC_24HR_5_UP	34		26
CAFFAREL_RESPONSE_TO_THC_8HR_3_DN	10		7
CAFFAREL_RESPONSE_TO_THC_8HR_3_UP	5		Rejected!
CAFFAREL_RESPONSE_TO_THC_8HR_5_DN	11		8
CAFFAREL_RESPONSE_TO_THC_8HR_5_UP	16		10
CAFFAREL_RESPONSE_TO_THC_DN	31		23
CAFFAREL_RESPONSE_TO_THC_UP	33		25
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_DN	50		35
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP	121		76
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN	455		337
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP	380		230
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN	460		325
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP	450		293
CHEN_HOXA5_TARGETS_6HR_DN	6		Rejected!
CHEN_HOXA5_TARGETS_6HR_UP	10		8
CHEN_HOXA5_TARGETS_9HR_DN	41		31
CHEN_HOXA5_TARGETS_9HR_UP	223		147
CHENG_IMPRINTED_BY_ESTRADIOL	110		71
CHIN_BREAST_CANCER_COPY_NUMBER_DN	16		11
CHIN_BREAST_CANCER_COPY_NUMBER_UP	27		23
CHUANG_OXIDATIVE_STRESS_RESPONSE_DN	11		10
CHUANG_OXIDATIVE_STRESS_RESPONSE_UP	28		24
CLIMENT_BREAST_CANCER_COPY_NUMBER_DN	8		6
CLIMENT_BREAST_CANCER_COPY_NUMBER_UP	23		21
CORDENONSI_YAP_CONSERVED_SIGNATURE	57		49
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN	23		18
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP	34		26
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1	528		357
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_2	473		210
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_3	720		477
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_4	307		202
CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5	482		324
DAIRKEE_CANCER_PRONE_RESPONSE_BPA	51		44
DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2	118		97
DAIRKEE_CANCER_PRONE_RESPONSE_E2	28		23
DAIRKEE_TERT_TARGETS_DN	124		81
DAIRKEE_TERT_TARGETS_UP	380		271
DITTMER_PTHLH_TARGETS_DN	73		59

DITTMER_PTHLH_TARGETS_UP	112	97
DOANE_BREAST_CANCER_CLASSES_DN	34	30
DOANE_BREAST_CANCER_CLASSES_UP	72	44
DOANE_BREAST_CANCER_ESR1_DN	48	41
DOANE_BREAST_CANCER_ESR1_UP	112	83
DOANE_RESPONSE_TO_ANDROGEN_DN	241	182
DOANE_RESPONSE_TO_ANDROGEN_UP	184	108
E2F3_UP.V1_DN	183	73
E2F3_UP.V1_UP	196	120
EINAV_INTERFERON_SIGNATURE_IN_CANCER	27	19
ENGELMANN_CANCER_PROGENITORS_DN	70	40
ENGELMANN_CANCER_PROGENITORS_UP	48	42
FARMER_BREAST_CANCER_APOCRINE_VS_BASAL	330	245
FARMER_BREAST_CANCER_APOCRINE_VS_LUMINAL	326	235
FARMER_BREAST_CANCER_BASAL_VS_LUMINAL	330	241
FARMER_BREAST_CANCER_CLUSTER_1	44	25
FARMER_BREAST_CANCER_CLUSTER_2	33	30
FARMER_BREAST_CANCER_CLUSTER_4	16	14
FARMER_BREAST_CANCER_CLUSTER_5	19	18
FARMER_BREAST_CANCER_CLUSTER_6	16	14
FARMER_BREAST_CANCER_CLUSTER_7	20	13
FARMER_BREAST_CANCER_CLUSTER_8	7	Rejected!
FINAK_BREAST_CANCER_SDPD_SIGNATURE	26	21
FINETTI_BREAST_CANCER_KINOME_GREEN	16	15
FINETTI_BREAST_CANCER_KINOME_RED	16	15
FINETTI_BREAST_CANCERS_KINOME_BLUE	21	17
FINETTI_BREAST_CANCERS_KINOME_GRAY	15	13
FOURNIER_ACINAR_DEVELOPMENT_EARLY_DN	6	Rejected!
FOURNIER_ACINAR_DEVELOPMENT_EARLY_UP	21	13
FOURNIER_ACINAR_DEVELOPMENT_LATE_2	277	216
FOURNIER_ACINAR_DEVELOPMENT_LATE_DN	21	19
FOURNIER_ACINAR_DEVELOPMENT_LATE_UP	11	9
FRASOR_RESPONSE_TO ESTRADIOL_DN	82	65
FRASOR_RESPONSE_TO ESTRADIOL_UP	37	32
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_DN	50	46
FRASOR_RESPONSE_TO_SERM_OR_FULVESTRANT_UP	24	14
FRASOR_TAMOXIFEN_RESPONSE_DN	11	8
FRASOR_TAMOXIFEN_RESPONSE_UP	51	38
FUJII_YBX1_TARGETS_DN	202	170
FUJII_YBX1_TARGETS_UP	43	31
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN	180	101
GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_UP	119	79
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN	335	184
GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_UP	78	51
GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN	1781	Rejected!
GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP	1142	861
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN	234	182
GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP	552	422
GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN	770	558
GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP	612	470
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_DN	84	66
GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP	211	167
GU_PDEF_TARGETS_DN	39	28
GU_PDEF_TARGETS_UP	71	64
GYORFFY_DOXORUBICIN_RESISTANCE	56	35
GYORFFY_MITOXANTRONE_RESISTANCE	57	36
HAN_SATB1_TARGETS_DN	442	319
HAN_SATB1_TARGETS_UP	395	274
HEDENFALK_BREAST_CANCER_BRACX_DN	20	15
HEDENFALK_BREAST_CANCER_BRACX_UP	20	14
HEDENFALK_BREAST_CANCER_BRCA1_VS_BRCA2	163	130
HEDENFALK_BREAST_CANCER_HEREDITARY_VS_SPORADIC	50	38
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETAXEL_2NM_DN	25	21
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETAXEL_2NM_UP	81	58
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETAXEL_4NM_DN	7	7
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETAXEL_4NM_UP	23	16
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_DN	38	31
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_UP	36	25
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_DN	19	10
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP	64	49
HESSON_TUMOR_SUPPRESSOR_CLUSTER_3P21_3	7	6
HOFFMAN_CLOCK_TARGETS_DN	10	8
HOFFMAN_CLOCK_TARGETS_UP	11	8
HONMA_DOCETAXEL_RESISTANCE	34	26
HONRADO_BREAST_CANCER_BRCA1_VS_BRCA2	18	16
HOOI_ST7_TARGETS_DN	123	67
HOOI_ST7_TARGETS_UP	94	56
HUANG_DASATINIB_RESISTANCE_DN	69	48
HUANG_DASATINIB_RESISTANCE_UP	81	63
HUPER_BREAST_BASAL_VS_LUMINAL_DN	59	43
HUPER_BREAST_BASAL_VS_LUMINAL_UP	54	38

IYENGAR_RESPONSE_TO_ADIPOCYTE_FACTORS	10	9
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_DN	43	34
JAZAERI_BREAST_CANCER_BRCA1_VS_BRCA2_UP	49	38
JOHNSTONE_PARVB_TARGETS_1_DN	63	42
JOHNSTONE_PARVB_TARGETS_1_UP	7	Rejected!
JOHNSTONE_PARVB_TARGETS_2_DN	336	228
JOHNSTONE_PARVB_TARGETS_2_UP	140	104
JOHNSTONE_PARVB_TARGETS_3_DN	918	602
JOHNSTONE_PARVB_TARGETS_3_UP	430	306
KEGG_HOMOLOGOUS_RECOMBINATION	28	23
KRAS.600.LUNG.BREAST_UP.V1_DN	289	186
KRAS.600.LUNG.BREAST_UP.V1_UP	288	183
KRAS.BREAST_UP.V1_DN	145	81
KRAS.BREAST_UP.V1_UP	146	92
KRAS.LUNG.BREAST_UP.V1_DN	145	92
KRAS.LUNG.BREAST_UP.V1_UP	145	95
LANDEMAINE_LUNG_METASTASIS	21	13
LANDIS_ERBB2_BREAST_PRENEOPLASTIC_DN	55	45
LANDIS_ERBB2_BREAST_PRENEOPLASTIC_UP	20	17
LANDIS_ERBB2_BREAST_TUMORS_324_DN	149	123
LANDIS_ERBB2_BREAST_TUMORS_324_UP	150	121
LANDIS_ERBB2_BREAST_TUMORS_65_DN	37	32
LANDIS_ERBB2_BREAST_TUMORS_65_UP	22	18
LE_SKI_TARGETS_DN	8	7
LE_SKI_TARGETS_UP	17	13
LIEN_BREAST_CARCINOMA_METAPLASTIC	35	32
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_DN	114	65
LIEN_BREAST_CARCINOMA_METAPLASTIC_VS_DUCTAL_UP	83	63
LIU_BREAST_CANCER	30	19
LIU_COMMON_CANCER_GENES	79	43
LIU_LIVER_CANCER	38	26
LIU_NASOPHARYNGEAL_CARCINOMA	70	51
LIU_TOPBP1_TARGETS	16	9
MACLACHLAN_BRCA1_TARGETS_DN	16	14
MACLACHLAN_BRCA1_TARGETS_UP	21	17
MAEKAWA_ATF2_TARGETS	24	20
MARCHINI_TRABECTEDIN_RESISTANCE_DN	49	38
MARCHINI_TRABECTEDIN_RESISTANCE_UP	21	17
MASSARWEH_RESPONSE_TO ESTRADIOL	61	44
MASSARWEH_TAMOXIFEN_RESISTANCE_DN	258	159
MASSARWEH_TAMOXIFEN_RESISTANCE_UP	578	375
MCBRYAN_PUBERTAL_BREAST_3_4WK_DN	39	30
MCBRYAN_PUBERTAL_BREAST_3_4WK_UP	214	172
MCBRYAN_PUBERTAL_BREAST_4_5WK_DN	196	158
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP	271	228
MCBRYAN_PUBERTAL_BREAST_5_6WK_DN	137	98
MCBRYAN_PUBERTAL_BREAST_5_6WK_UP	116	99
MCBRYAN_PUBERTAL_BREAST_6_7WK_DN	79	68
MCBRYAN_PUBERTAL_BREAST_6_7WK_UP	197	151
MCBRYAN_PUBERTAL_TGFB1_TARGETS_DN	62	58
MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP	169	151
MCBRYAN_TERMINAL_END_BUD_DN	7	Rejected!
MCBRYAN_TERMINAL_END_BUD_UP	12	10
MIKI_COEXPRESSED_WITH_CYP19A1	7	7
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_DN	24	19
MISHRA_CARCINOMA_ASSOCIATED_FIBROBLAST_UP	24	18
MORF_BRCA1	264	195
MYC_UP.V1_DN	182	78
MYC_UP.V1_UP	186	97
NADERI_BREAST_CANCER_PROGNOSIS_DN	18	17
NADERI_BREAST_CANCER_PROGNOSIS_UP	50	39
NAGASHIMA_EGF_SIGNALING_UP	58	49
NAGASHIMA_NRG1_SIGNALING_DN	58	36
NAGASHIMA_NRG1_SIGNALING_UP	176	149
NAM_FXYD5_TARGETS_DN	18	17
NIKOLSKY_BREAST_CANCER_10Q22_AMPLICON	9	5
NIKOLSKY_BREAST_CANCER_11Q12_Q14_AMPLICON	158	98
NIKOLSKY_BREAST_CANCER_12Q13_Q21_AMPLICON	46	34
NIKOLSKY_BREAST_CANCER_12Q24_AMPLICON	15	9
NIKOLSKY_BREAST_CANCER_14Q22_AMPLICON	14	12
NIKOLSKY_BREAST_CANCER_15Q26_AMPLICON	22	10
NIKOLSKY_BREAST_CANCER_16P13_AMPLICON	120	68
NIKOLSKY_BREAST_CANCER_16Q24_AMPLICON	53	32
NIKOLSKY_BREAST_CANCER_17P11_AMPLICON	10	9
NIKOLSKY_BREAST_CANCER_17Q11_Q21_AMPLICON	133	80
NIKOLSKY_BREAST_CANCER_17Q21_Q25_AMPLICON	335	200
NIKOLSKY_BREAST_CANCER_19P13_AMPLICON	5	5
NIKOLSKY_BREAST_CANCER_19Q13.1_AMPLICON	22	Rejected!
NIKOLSKY_BREAST_CANCER_19Q13.4_AMPLICON	7	Rejected!
NIKOLSKY_BREAST_CANCER_1Q21_AMPLICON	38	31
NIKOLSKY_BREAST_CANCER_1Q32_AMPLICON	13	10

NIKOLSKY_BREAST_CANCER_20P13_AMPLICON	8	7
NIKOLSKY_BREAST_CANCER_20Q11_AMPLICON	31	22
NIKOLSKY_BREAST_CANCER_20Q12_Q13_AMPLICON	149	85
NIKOLSKY_BREAST_CANCER_21Q22_AMPLICON	16	12
NIKOLSKY_BREAST_CANCER_22Q13_AMPLICON	17	8
NIKOLSKY_BREAST_CANCER_5P15_AMPLICON	26	20
NIKOLSKY_BREAST_CANCER_6P24_P22_AMPLICON	21	13
NIKOLSKY_BREAST_CANCER_7P15_AMPLICON	11	11
NIKOLSKY_BREAST_CANCER_7P22_AMPLICON	38	23
NIKOLSKY_BREAST_CANCER_7Q21_Q22_AMPLICON	76	44
NIKOLSKY_BREAST_CANCER_8P12_P11_AMPLICON	57	38
NIKOLSKY_BREAST_CANCER_8Q12_Q22_AMPLICON	132	86
NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON	157	87
NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER	94	56
NIKOLSKY_OVERCONNECTED_IN_BREAST_CANCER	22	19
PACHER_TARGETS_OF_IGF1_AND_IGF2_UP	35	30
PECE_MAMMARY_STEM_CELL_DN	146	102
PECE_MAMMARY_STEM_CELL_UP	146	99
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_1	46	37
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_3	20	13
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_4	110	77
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_5	11	8
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_6	29	20
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7	403	273
PEDERSEN_TARGETS_OF_611CTF_ISOFORM_OF_ERBB2	76	55
POOLA_INVASIVE_BREAST_CANCER_DN	134	97
POOLA_INVASIVE_BREAST_CANCER_UP	288	215
PUJANA_ATM_PCC_NETWORK	1442	Rejected!
PUJANA_BRCA1_PCC_NETWORK	1652	Rejected!
PUJANA_BRCA2_PCC_NETWORK	423	336
PUJANA_BRCA_CENTERED_NETWORK	117	103
PUJANA_BREAST_CANCER_LIT_INT_NETWORK	101	88
PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_DN	9	6
PUJANA_BREAST_CANCER_WITH_BRCA1_MUTATED_UP	56	48
PUJANA_CHEK2_PCC_NETWORK	779	603
PUJANA_XPRSS_INT_NETWORK	168	138
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_DN	159	125
RAY_TUMORIGENESIS_BY_ERBB2_CDC25A_UP	104	80
RIGGINS_TAMOXIFEN_RESISTANCE_DN	220	174
RIGGINS_TAMOXIFEN_RESISTANCE_UP	66	58
RIZKI_TUMOR_INVASIVENESS_2D_DN	64	56
RIZKI_TUMOR_INVASIVENESS_2D_UP	69	56
RIZKI_TUMOR_INVASIVENESS_3D_DN	270	201
RIZKI_TUMOR_INVASIVENESS_3D_UP	210	163
ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_DN	26	16
ROYLANCE_BREAST_CANCER_16Q_COPY_NUMBER_UP	63	33
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_DN	84	68
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP	351	266
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_DN	30	27
SEITZ_NEOPLASTIC_TRANSFORMATION_BY_8P_DELETION_UP	73	54
SMID_BREAST_CANCER_BASAL_DN	701	476
SMID_BREAST_CANCER_BASAL_UP	648	493
SMID_BREAST_CANCER_ERBB2_DN	5	Rejected!
SMID_BREAST_CANCER_ERBB2_UP	147	98
SMID_BREAST_CANCER_LUMINAL_A_DN	18	15
SMID_BREAST_CANCER_LUMINAL_A_UP	84	63
SMID_BREAST_CANCER_LUMINAL_B_DN	564	412
SMID_BREAST_CANCER_LUMINAL_B_UP	172	121
SMID_BREAST_CANCER_NORMAL_LIKE_DN	6	5
SMID_BREAST_CANCER_NORMAL_LIKE_UP	476	348
SMID_BREAST_CANCER_RELAPSE_IN_BONE_DN	315	238
SMID_BREAST_CANCER_RELAPSE_IN_BONE_UP	97	64
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_DN	85	58
SMID_BREAST_CANCER_RELAPSE_IN_BRAIN_UP	39	37
SMID_BREAST_CANCER_RELAPSE_IN_LIVER_DN	10	10
SMID_BREAST_CANCER_RELAPSE_IN_LIVER_UP	6	6
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_DN	37	25
SMID_BREAST_CANCER_RELAPSE_IN_LUNG_UP	21	18
SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_DN	27	16
SMID_BREAST_CANCER_RELAPSE_IN_PLEURA_UP	6	6
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_DN	52	35
SOTIRIOU_BREAST_CANCER_GRADE_1_VS_3_UP	151	118
SRC_UP.V1_DN	179	95
SRC_UP.V1_UP	188	107
STEIN_ESR1_TARGETS	85	70
STEIN_ESRRA_TARGETS	535	379
STEIN_ESRRA_TARGETS_DN	105	65
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_DN	41	35
STEIN_ESRRA_TARGETS_RESPONSIVE_TO_ESTROGEN_UP	31	21
STEIN_ESRRA_TARGETS_UP	388	286
STEIN_ESTROGEN_RESPONSE_NOT_VIA_ESRRA	18	16

STREICHER_LSM1_TARGETS_DN	19	15
STREICHER_LSM1_TARGETS_UP	44	37
SUBTIL_PROGESTIN_TARGETS	36	29
TAVAZOIE_METASTASIS	108	65
THEODOROU_MAMMARY_TUMORIGENESIS	31	24
THILLAINADESAN_ZNF217_TARGETS_DN	9	6
THILLAINADESAN_ZNF217_TARGETS_UP	44	31
TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULAR_DN	7	Rejected!
TURASHVILI_BREAST_CARCINOMA_DUCTAL_VS_LOBULAR_UP	21	13
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN	198	132
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP	44	35
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_DN	69	45
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_LOBULAR_NORMAL_UP	73	57
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_DN	91	63
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP	69	53
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN	74	57
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_UP	94	66
TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_DN	7	Rejected!
TURASHVILI_BREAST_NORMAL_DUCTAL_VS_LOBULAR_UP	68	34
V\$AP2_Q3	251	194
V\$AP2_Q6	258	184
V\$AP2_Q6_01	272	192
V\$AP2GAMMA_01	250	179
V\$HMGY_Q6	248	174
V\$STAT1_02	252	174
V\$STAT1_03	248	174
VANTVEER_BREAST_CANCER_BRCA1_DN	44	29
VANTVEER_BREAST_CANCER_BRCA1_UP	36	30
VANTVEER_BREAST_CANCER_ESR1_DN	240	185
VANTVEER_BREAST_CANCER_ESR1_UP	167	111
VANTVEER_BREAST_CANCER_METASTASIS_DN	121	84
VANTVEER_BREAST_CANCER_METASTASIS_UP	56	34
VANTVEER_BREAST_CANCER_POOR_PROGNOSIS	55	32
VETTER_TARGETS_OF_PRKCA_AND_ETS1_DN	16	10
VETTER_TARGETS_OF_PRKCA_AND_ETS1_UP	16	12
WANG_METASTASIS_OF_BREAST_CANCER	15	9
WANG_METASTASIS_OF_BREAST_CANCER_ESR1_DN	30	22
WANG_METASTASIS_OF_BREAST_CANCER_ESR1_UP	22	17
WANG_METHYLATED_IN_BREAST_CANCER	35	32
WILLIAMS_ESR1_TARGETS_DN	6	Rejected!
WILLIAMS_ESR1_TARGETS_UP	26	22
WILLIAMS_ESR2_TARGETS_DN	11	8
WILLIAMS_ESR2_TARGETS_UP	28	23
WILSON_PROTEASES_AT_TUMOR_BONE_INTERFACE_DN	5	5
WILSON_PROTEASES_AT_TUMOR_BONE_INTERFACE_UP	21	19
WINTER_HYPOXIA_DN	52	38
WINTER_HYPOXIA_METAGENE	242	198
WINTER_HYPOXIA_UP	92	61
WONG_MITOCHONDRIA_GENE_MODULE	217	178
WONG_PROTEASOME_GENE_MODULE	49	42
ZHANG_BREAST_CANCER_PROGENITORS_DN	145	104
ZHANG_BREAST_CANCER_PROGENITORS_UP	425	308
ZHU_SKIL_TARGETS_DN	9	9
ZHU_SKIL_TARGETS_UP	20	17
ZUCCHI_METASTASIS_DN	44	36
ZUCCHI_METASTASIS_UP	43	36